INTRODUCTION {#sec1-1}
============

Penile carcinoma is a rare malignant tumor, accounting for \<1% of adult male cancers in Europe and North America.[@ref1] However, its incidence in South America, Africa, and some parts of Asia may be as high as 10%, and approximately 26 300 new cases are diagnosed each year in men who are older than 66 years.[@ref2] The disease is characterized by an increased incidence in older men, with an average age at diagnosis of 60 years. The peak incidence of penile cancer (PeCa) occurs at the age of 70 years.[@ref3][@ref4] No consensus is available regarding the age distribution of PeCa cases.

Studies have identified several contributing factors for PeCa, including phimosis, smoking, and chronic inflammatory states.[@ref5] In addition, lesions on the glans are directly linked to poor hygiene.

Human papillomavirus (HPV) infection is associated with anogenital cancer (including cervical, vaginal, vulvar, penile, and anal cancers), oropharyngeal cancer, and genital warts. The HPV vaccination significantly reduces the incidence of anogenital cancer and genital warts.[@ref6] However, although the success of the quadrivalent vaccine against HPV has led to substantial decreases in HPV-associated infections and cancers in women, studies have not demonstrated similar success in men, specifically in relation to PeCa and penile precancerous lesions. Determining the pathogenesis of HPV infection may provide valuable therapeutic targets to treat this rare and difficult disease.[@ref5] The aim of this study was to evaluate the prevalence of HPV in penile malignant tumor tissue samples in the most recent decade and to determine the relationship between histological types of PeCa and HPV to further understand the development of PeCa.

MATERIALS AND METHODS {#sec1-2}
=====================

 {#sec2-1}

### Search strategy and selection criteria {#sec3-1}

This systematic review and meta-analysis is reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement and was registered at the International Prospective Register of Systematic Reviews (No. CRD42018086094; available at: <https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=86094>).

An extensive literature search was conducted by two independent authors to identify all relevant studies published between January 1, 2007, and December 29, 2017, by searching Embase, PubMed, Cochrane Library, and Web of Science. With no language restrictions, we used the following combined text and Medical Subject Headings (MeSH) terms: "penile neoplasms" and "human papillomavirus." The complete search strategy used for PubMed was as follows: (Penile Neoplasms) OR (Neoplasms, Penis) OR (Penis Neoplasms) OR (Neoplasm, Penis) OR (Penis Neoplasm) OR (Neoplasms, Penile) OR (Neoplasm, Penile) OR (Penile Neoplasm) OR (Cancer of Penis) OR (Penis Cancers) OR (Cancer of the Penis) OR (Penis Cancer) OR (Cancer, Penis) OR (Cancers, Penis) OR (Penile Cancer) OR (Cancer, Penile) OR (Cancers, Penile) OR (Penile Cancers) AND (Human Papillomavirus). We considered all potentially eligible studies for review irrespective of the primary outcome or language. We also performed a manual search using the reference lists of key articles published in English and assessed the risk for bias according to the Agency for Healthcare Research and Quality (AHRQ),[@ref7] including studies with intermediate and high grades.

### Study selection and data extraction {#sec3-2}

We regarded studies as eligible for inclusion if cases of invasive PeCa had HPV data available and if HPV DNA was detected in the formalin-fixed paraffin-embedded (FFPE) or paraffin-embedded (PE) tissue samples with polymerase chain reaction (PCR) technology. The reference lists of the identified articles were also reviewed for additional publications. A comprehensive effort to exclude repetitive cases from the final analysis was undertaken. When repeated histological samples were identified, the article that used the most sensitive HPV-DNA detection technique was selected.

The authors were directly contacted if anything doubtful was found, and the article in question was excluded if no answer was received. Studies with sample sizes fewer than five were also excluded. The following information was collected: the first author, year of publication, journal title, country of origin, diagnosis date, HPV detection methods, PCR primers used for HPV DNA, sample size, sample preparation, and histological type, as well as the overall HPV DNA prevalence. Histological groups for analysis corresponded to the World Health Organization (WHO) histological classification of penile cancers.[@ref8]

HPV genotypes were divided into low and high risk following the epidemiologic criteria established by Muñoz *et al*.[@ref9] Genotypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82 were classified as high risk, 26, 53, and 66 were classified as probable high-risk types, and genotypes 6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81, and CP6108 are classified as low risk for producing malignant transformation when they invade the epithelial cells of the cervix. HPV genotype-specific contributions for the HPV 16, 18, 31, 33, 35, 45, and 56 subtypes were estimated as a more relative proportion of high-risk HPV (hrHPV) among all HPV-positive cases, and types 6 and 11 were estimated to be relatively low-risk HPV (lrHPV). Combined HPV infection samples were assigned to the appropriate group according to the original article description or classified as "other" if the article did not provide the necessary information.

### Quality assessment {#sec3-3}

The methodological quality of the included studies was assessed using an 11-item checklist recommended by the AHRQ statement (available at <https://www.ncbi.nlm.nih.gov/books/NBK35156/>).[@ref10] The item was scored "0" if the answer was "NO" or "UNCLEAR," and the item was scored "1" if the answer was "YES." Article quality was assessed as follows: low quality = 0--3; moderate quality = 4--7; and high quality = 8--11.

### Statistical analyses {#sec3-4}

We assessed the overall HPV prevalence with the corresponding 95% confidence interval (CI) by dividing the number of subjects for each histological group by the number of HPV-positive cases. The Chi-squared test was also used to evaluate the relationship between HPV and penile carcinoma. The statistical package Stata V.15.0 (Stata Corporation, College Station, TX, USA), Revman 5.3 (Cochrane Collaborative, Oxford, UK), SPSS 22.0 (SPSS Inc., Chicago, IL, USA), and Microsoft Office 2007 (Microsoft, Redmond, WA, USA) were used for calculations and statistical analyses. Heterogeneity among the studies was measured by a random-effects model using the Chi-squared test, *P* values, and *I*^2^ statistics. *P* \< 0.05 was considered statistically significant. A previously used method of evidence-based medicine was used to produce a forest map of noncomparative binary data.[@ref11][@ref12]

RESULTS {#sec1-3}
=======

 {#sec2-2}

### Description of studies {#sec3-5}

A total of 22 studies[@ref4][@ref13][@ref14][@ref15][@ref16][@ref17][@ref18][@ref19][@ref20][@ref21][@ref22][@ref23][@ref24][@ref25][@ref26][@ref27][@ref28][@ref29][@ref30][@ref31][@ref32] complied with the inclusion criteria, which included 1664 patients with penile carcinoma (**[Figure 1](#F1){ref-type="fig"}**). Through AHRQ estimation, 7 articles[@ref17][@ref24][@ref26][@ref28][@ref29][@ref30][@ref31] were considered high quality, and 15 articles[@ref4][@ref13][@ref14][@ref15][@ref16][@ref18][@ref19][@ref20][@ref21][@ref22][@ref23][@ref25][@ref27][@ref32][@ref33] were considered moderate quality (**[Supplementary Table 1](#T1){ref-type="table"}**). The overall prevalence of HPV positivity in patients with penile tumors was approximately 51% (95% CI: 43%--60%; **[Figure 2](#F2){ref-type="fig"}**). Overall, 73.8% of the penile carcinoma cases were squamous cell carcinoma (SCC). The most frequently used PCR primers were PCR GP5+6+ and PCR SPF-10. The data were analyzed for differences with respect to HPV DNA detection between PCR GP5+6+ and PCR SPF-10. The results were evaluated by Pearson\'s Chi-squared test, and no significance (χ^2^ = 2.938, df = 1, *P* \> 0.05) was detected (**[Supplementary Table 2](#T2){ref-type="table"}**).

![Flowchart of literature screening.](AJA-21-375-g001){#F1}

###### 

Type-specific prevalence of human papillomavirus in penile carcinomas by study-relevant items and histological type

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *Reference*                    *Journal (year)*                   *Study area*       *Mean age (year)*   *Method of detection and primers*              *Sample*         *Sample Number of case*   *Overall HPV positive rate Number of cases (%)*   *Histology vegetative and number of cases*   *Relative HPV Prevalence, n (%)*                                                   
  ------------------------------ ---------------------------------- ------------------ ------------------- ---------------------------------------------- ---------------- ------------------------- ------------------------------------------------- -------------------------------------------- ---------------------------------- ------------ ----------- ---------- ----------- ---
  LA                             *J Med Virol (2017)*               Brazil             58 (26--92)         PCR MY09/11                                    TFTE             122                       79 (64.8)                                         --                                           --                                                                                 

  Damásdi                        *Pathol Oncol Res (2015)*          Hungary            61.2 (44--87)       PCR SPF10                                      FFPE             35                        14 (40.0)                                         --                                                                                                                              

  lsaura                         *BMC Urol (2015)*                  Brazil             66±17.10            PCR/Nested automated sequencing                FFPE             76                        48 (63.2)                                         --                                           --                                                                                 

  Hernandez                      *Front Oncol (2014)*               USA                                    PCR-based Linear Array and INNO -LiPA assays   FFPE             79                        50 (63.3)                                         Keratinizing (53)                            30 (56.6)                                                                          

  Basaloid or warty-SCC (11)     9 (81.8)                                                                                                                                                                                                                                                                                                                                              

  Other SCC (15)                 11 (73.3)                                                                                                                                                                                                                                                                                                                                             

  Djajadiningrat                 *J Urol (2014)*                    Netherlands        63 (54--71)         PCR GP5+6+                                     FFPE             212                       53 (24.1)                                         SCC (183)                                    44 (24.0)                                                                          

  Verruceus (5)                  0 (0)                                                                                                                                                                                                                                                                                                                                                 

  Warty (5)                      3 (60.0)                                                                                                                                                                                                                                                                                                                                              

  Basaloid (5)                   4 (80.0)                                                                                                                                                                                                                                                                                                                                              

  Basaloid-SCC (2)               1 (50.0)                                                                                                                                                                                                                                                                                                                                              

  Papillar (9)                   1 (11.1)                                                                                                                                                                                                                                                                                                                                              

  Others (3)                     0 (0)                                                                                                                                                                                                                                                                                                                                                 

  Lebelo                         *J Med Virol (2014)*               South Africa       49.8 (18--87)       TaqMan-based qPCR                              FFPE             44                        35 (79.5)                                         Keratinizing SCC (4)                         3 (75.0)                                                                           

  Verrucous (9)                  8 (88.9)                                                                                                                                                                                                                                                                                                                                              

  Papillary SCC (2)              1 (50.0)                                                                                                                                                                                                                                                                                                                                              

  Others (20)                    --                                                                                                                                                                                                                                                                                                                                                    

  Do                             *Br J Cancer (2013)*               Vietnam            53 (51--57)         PCR SPF10 and HPV-16 E6                        PE               120                       27 (22.5)                                         Basaloid (3)                                 2 (66.7)                                                                           

  Keratinising (83)              19 (22.9)                                                                                                                                                                                                                                                                                                                                             

  Non-keratinising (20)          3 (15.0)                                                                                                                                                                                                                                                                                                                                              

  Verrucous (8)                  2 (25.0)                                                                                                                                                                                                                                                                                                                                              

  Warty (2)                      0                                                                                                                                                                                                                                                                                                                                                     

  Undetermined (4)               1 (25.0)                                                                                                                                                                                                                                                                                                                                              

  Chaux                          *World J Urol (2013)*              Paraguay           62                  PCR SPF-10                                     Tumor tissue     61                        29 (47.5)                                         No warty/basaloid --features (53)            9 (17.0)                                                                           

  Warty/basaloid-features (36)   23 (63.9)                                                                                                                                                                                                                                                                                                                                             

  D'Hauwers                      *Vaccine (2012)*                   Belgium            --                  Real-time quantitative PCR                     FFPE             55                        24 (43.6)                                         --                                           --                                                                                 

  Cubilla                        *Am J Surg Pathol (2010)*          Paraguay           61 (16--95)         PCR SPF-10                                                      202                       64 (31.7)                                         Basaloid (--)                                19                                                                                 

  Warty-basaloid (--)            9                                                                                                                                                                                                                                                                                                                                                     

  Warty (--)                     8                                                                                                                                                                                                                                                                                                                                                     

  Usual (--)                     18                                                                                                                                                                                                                                                                                                                                                    

  Papillary (--)                 6                                                                                                                                                                                                                                                                                                                                                     

  Mixed (--)                     2                                                                                                                                                                                                                                                                                                                                                     

  Krustrup                       *Int J Exp Pathol (2009)*          Denmark            --                  PCR GP5+/6+                                    FFPE             145                       89 (61.4)                                         Keratinizing (68)                            31 (45.6)                                                                          

  Basaloid (33)                  32 (97.0)                                                                                                                                                                                                                                                                                                                                             

  Warty (11)                     7 (63.6)                                                                                                                                                                                                                                                                                                                                              

  Verrucous (16)                 1 (6.3)                                                                                                                                                                                                                                                                                                                                               

  Giant cell (3)                 3 (100.0)                                                                                                                                                                                                                                                                                                                                             

  Combined types (12)            10 (83.3)                                                                                                                                                                                                                                                                                                                                             

  SENBA                          *Oncol Lett (2009)*                Japan              --                  PCR SPF10                                      FFPE             16                        12 (75.0)                                         Keratinizing (10)                            8 (80.0)                                                                           

  Nonkeratinizing (4)            3 (75.0)                                                                                                                                                                                                                                                                                                                                              

  Verrucous (2)                  1 (50.0)                                                                                                                                                                                                                                                                                                                                              

  Scheiner                       *Int Braz J Urol (2008)*           Brazil             --                  PCR MY09/MY11                                  FFPE             80                        58 (72.5)                                         --                                           --                                                                                 

  Guerrero                       *B J U Int (2008)*                 Spain              67.6                PCRGP5+/GP6+biotinylated primers               FFPE             24                        11 (45.8)                                         Squamous (17)                                --                                                                                 

  Warty (4)                      --                                                                                                                                                                                                                                                                                                                                                    

  Verrucous (1)                  --                                                                                                                                                                                                                                                                                                                                                    

  Basaloid (2)                   --                                                                                                                                                                                                                                                                                                                                                    

  Yanagawa                       *Pathology (2008)*                 Japan              67.6 (46--87)       PCR-RFLP                                       FFPE             26                        3 (11.5)                                          --                                           --                                                                                 

  Tornesello                     *Int J Cancer (2008)*              Italy              --                  PCR MY09/MY11 and GP51/GP61                    FFPE             41                        19 (46.3)                                         --                                           --                                                                                 

  Madsen                         *Am Assoc Cancer Res (2008)*       Denmark            --                  PCR GP5 +/6 +                                  FFPE             71                        25 (35.2)                                         Keratinizing (37)                            --                                                                                 

  Verrucous (2)                  --                                                                                                                                                                                                                                                                                                                                                    

  Basaloid (1)                   --                                                                                                                                                                                                                                                                                                                                                    

  Sarcomatoid (1)                --                                                                                                                                                                                                                                                                                                                                                    

  Prowse                         *Br J Dermatol (2007)*             UK                 --                  PCR SPF10                                      FFPE             26                        14 (53.8)                                         --                                           --                                                                                 

  Tornesello ML                  *Cancer Let (2008)*                Uganda             60.6±11.1           semi-nested PCR                                PE               17                        11 (64.7)                                         Keratinizing SCC (15)                        --                                                                                 

  Basaloid SCC (1)               --                                                                                                                                                                                                                                                                                                                                                    

  Verrucous SCC (1)              --                                                                                                                                                                                                                                                                                                                                                    

  Warty SCC (0)                  --                                                                                                                                                                                                                                                                                                                                                    

  Sarcomatoid (0)                --                                                                                                                                                                                                                                                                                                                                                    

                                                                    Italy              61±12.6             Semi-nested PCR                                PE               61                        29 (47.5)                                         Keratinizing (54)                            --                                                                                 

  Basaloid SCC (3)               --                                                                                                                                                                                                                                                                                                                                                    

  Verrucous (2)                  --                                                                                                                                                                                                                                                                                                                                                    

  Warty (1)                      --                                                                                                                                                                                                                                                                                                                                                    

  Sarcomatoid (1)                --                                                                                                                                                                                                                                                                                                                                                    

  Heideman                       *J Clin Oncol (2007)*              Germany            65 (27--92)         PCR GP5 +/6 +                                  FFPE             83                        46 (55.4)                                         Not-Specified (72)                           40 (55.6)                                                                          

  Verrucous (7)                  4 (57.1)                                                                                                                                                                                                                                                                                                                                              

  Warty (2)                      1 (50.0)                                                                                                                                                                                                                                                                                                                                              

  Sarcomatoid (2)                1 (50.0)                                                                                                                                                                                                                                                                                                                                              

  Protzel                        *Cellular Molecular Biol (2007)*   Germany            69.4 (35--89)       High Pure PCR\                                 FE               19                        7 (36.8)                                          Nonkeratinizing (4)                          2 (50.0)                                                                           
                                                                                                           Template                                                                                                                                                                                                                                                                    

  Keratinizing (9)               2 (22.2)                                                                                                                                                                                                                                                                                                                                              

  Papillary (1)                  0 (0)                                                                                                                                                                                                                                                                                                                                                 

  Verrucous (1)                  0 (0)                                                                                                                                                                                                                                                                                                                                                 

  Condylomatous (1)              0 (0)                                                                                                                                                                                                                                                                                                                                                 

  Basaloid (3)                   3 (100.0)                                                                                                                                                                                                                                                                                                                                             

  Pascual                        *Cellular Molecular Biol (2007)*   Spain              --                  PCR My09/My11 and GP5 +/GP6 +                                   49                        38 (77.5)                                                                                                                                                                         

  Total                                                                                                                                                                    1664                      785 (47.2)                                                                                     1465                                                                               

                                                                                                                                                                                                                                                                                                                                                                                       

  **Reference**                  **Hr HPV**                         **Subtotal (%)**   **Lr HPV**          **Subtotal (%)**                               **AHRQ score**                                                                                                                                                                                                               

                                                                                                                                                                                                                                                                                                                                                                                       

  **16**                         **18**                             **31**             **33**              **35**                                         **45**           **56**                    **Others**                                        **6**                                        **11**                             **Others**                                      

                                                                                                                                                                                                                                                                                                                                                                                       

  LA                             32 (40.5%)                         7 (8.9%)           7 (8.9%)            0                                              0                9 (11.4%)                 --                                                1 (1.3%)                                     56 (70.9)                          13 (16.5%)   6 (7.6%)    4 (5.1%)   23 (29.1)   6

  Damásdi                        11 (78.6%)                         0                  0                   0                                              0                0                         0                                                 2 (14.3%)                                    13 (92.9)                          0            0           1 (7.1%)   1 (7.1)     4

  lsaura                         10 (20.8%)                         4 (8.3%)           --                  --                                             --               1 (2.1%)                  --                                                --                                           --                                 --           6 (12.5%)   --         --          6

  Hernandez                      36 (72.0%)                         2 (4.0%)           0                   3 (6.0%)                                       1 (2.0%)         2 (4.0%)                  0                                                 5 (10.0%)                                    49 (98.0)                          1 (2.0%)     0           0          1 (2.0)     7

  Djajadiningrat                 42 (79.2%)                         3 (5.7%)           1 (1.9%)            4 (7.5%)                                       0                2 (3.8%)                  1 (1.9%)                                          0                                            53 (100)                           --           --          --         --          6

  Lebelo                         2 (5.7%)                           0                  0                   0                                              0                1 (2.8%)                  0                                                 0                                            3 (8.6)                            0            0           0          0           8

  4 (11.4%)                      4 (11.4%)                          0                  0                   0                                              0                0                         0                                                 8 (22.8)                                     1 (2.8%)                           7 (20.0%)    0           8 (22.8)               

  0                              0                                  0                  0                   0                                              0                0                         0                                                 0                                            0                                  1 (2.8%)     0           1 (2.8)                

  Do                             24 (88.9%)                         --                 --                  --                                             --               --                        --                                                --                                           --                                 --           --          --         --          5

  Chaux                          --                                 --                 --                  --                                             --               --                        --                                                --                                           --                                 --           --          --         --          7

  D'Hauwers                      17                                                                        1                                                               --                        1                                                 3                                            22 (91.7)                          1            1           0          2 (8.3)     4

  Cubilla                        13                                 1                  --                  --                                             1                0                         --                                                4                                            19                                 0            0           0          0           5

  4                              0                                  --                 --                  0                                              0                --                        3                                                 7                                            2                                  0            0           2                      

  3                              1                                  --                 --                  1                                              0                --                        2                                                 7                                            0                                  0            1           1                      

  10                             1                                  --                 --                  0                                              2                --                        3                                                 16                                           1                                  1            0           2                      

  5                              0                                  --                 --                  0                                              0                --                        1                                                 6                                            0                                  0            0           0                      

  1                              0                                  --                 --                  0                                              0                --                        3                                                 6                                            0                                  0            0           0                      

  Krustrup                       78 (87.6%)                         0                  1 (1.1%)            3 (3.4%)                                       1 (1.1%)         1 (1.1%)                  1 (1.1%)                                          1 (1.1%)                                     86 (96.6)                          5 (5.6%)     1 (1.1%)    1 (1.1%)   7 (7.9)     6

  SENBA                          0                                  1 (8.3%)           --                  --                                             --               --                        --                                                10 (83.3%)                                   --                                 --           --          --         --          7

  Scheiner                       12 (20.7%)                         1 (1.7%)           1 (1.7%)            1 (1.7%)                                       0                1 (1.7%)                  0                                                 0                                            16 (27.6)                          4 (6.9%)                            42 (72.4)   8

  Guerrero                       10 (90.9%)                         0                  0                   0                                              0                0                         0                                                 1 (9.1%)                                     11 (100.0)                         0            0           0          0           6

  Yanagawa                       --                                 --                 --                  --                                             --               --                        --                                                --                                           --                                 --           --          --         --          8

  Tornesello                     --                                 --                 --                  --                                             --               --                        --                                                --                                           --                                 --           --          --         --          5

  Madsen                         --                                 --                 --                  --                                             --               --                        --                                                --                                           24 (96.0)                          --           --          --         1 (4.0)     8

  Prowse                         10 (71.4%)                         1 (7.1%)           0                   0                                              0                0                         0                                                 1 (7.1%)                                     12 (85.7)                          1 (7.1%)     0           1 (7.1%)   2 (14.3)    8

  Tornesello ML                  7 (63.6%)                          0                  0                   0                                              0                0                         0                                                 3 (27.3%)                                    10 (90.9)                          1 (9.1%)     0           0          1 (9.1)     9

  26 (89.6%)                     2 (6.9%)                           0                  0                   1 (3.4%)                                       0                0                         0                                                 29 (100.0)                                                                      0            0           0                      

  Heideman                       22 (47.8%)                         2 (4.3%)           0                   0                                              0                2 (4.3%)                  1 (2.2%)                                          15 (32.6%)                                   44 (95.6)                          1 (2.2%)     0           0          2 (4.3)     5

  2 (4.3%)                       0                                  0                  0                   0                                              0                0                         2 (4.3%)                                                                                                                          0            0                                  

  0                              0                                  0                  0                   0                                              0                0                         0                                                                                              1 (100%)                           0            0                                  

  0                              0                                  0                  0                   0                                              0                0                         0                                                                                              0                                  0            0                                  

  Protzel                        1 (14.3%)                          --                 --                  --                                             --               --                        --                                                                                             1 (14.3)                           1 (14.3%)                           1 (14.3)    9

  2 (28.6%)                      --                                 --                 --                  --                                             --               --                        --                                                2 (28.6)                                                                                                                        

  0                              --                                 --                 --                  --                                             --               --                        --                                                0                                                                                                                               

  0                              --                                 --                 --                  --                                             --               --                        --                                                0                                                                                                                               

  0                              --                                 --                 --                  --                                             --               --                        --                                                0                                                                                                                               

  2 (28.6%)                      --                                 --                 --                  --                                             --               --                        --                                                2 (28.6)                                     1 (14.3%)                                                   1 (14.3)               

  Pascual                        32 (84.2%)                         4 (10.5%)          --                  --                                             --               --                        --                                                2 (5.3%)                                     38 (100.0)                         --           --          --         --          6

  Total                          418 (28.5%)                        34 (2.3%)          10 (0.7%)           12 (0.8%)                                      5 (0.3%)         21 (0.1%)                 4 (0.2%)                                          59 (4.0%)                                    539 (36.8)                         34 (2.3%)    23 (1.6%)   8 (0.5%)   97 (6.6)    
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

hr HPV: high-risk Human Papillomavirus; lr HPV: low-risk Human Papillomavirus; -- :no involve; PCR: polymerase chain reaction; TFTE: Tumor fragments stored in TE solution \[10-mM Tris hydrochloride (pH 7.5), 1mM ethylenediaminetetraacetic acid (EDTA)\]; FFPE: formalin-fixed paraffin-embedded; PE: paraffin embedded; AHRQ: The Agency for Healthcare Research and Quality; SCC: squamous cell carcinoma

![Comparison of the risk of HPV infection in penile cancer in different countries around the world. HPV: human papillomavirus; SE: standard error; IV: inverse variance methods; CI: confidence interval; df: degree of freedom.](AJA-21-375-g002){#F2}

###### 

The number of human papillomavirus-positive samples detected by two different primers

                *HPV*   *Total*   
  ------------- ------- --------- -----
  Group                           
   PCR G5+G6+   213     323       536
   PCR SPF10    146     279       425
  Total         359     602       961

*χ*^2^=2.938, df=1, *P*=0.087. HPV: human papillomavirus; PCR: polymerase chain reaction

### Description of HPV detection {#sec3-6}

Analyses of type-specific HPV prevalence rates were limited to 16 studies[@ref4][@ref16][@ref17][@ref18][@ref20][@ref21][@ref22][@ref23][@ref24][@ref25][@ref27][@ref28][@ref29][@ref30][@ref31][@ref32][@ref33] of SCC (*n* = 1270) with available data. Among these studies, approximately 19 HPV types were detected. Using all the cases tested as the denominator, the overall infection rate was 47.2% (95% CI: 31.0%--70.0%). The three most common types of HPV were HPV16 (28.5%), HPV18 (2.3%), and HPV6 (2.3%) (**[Supplementary Table 1](#T1){ref-type="table"}**). HPV18 and HPV 6 were detected in 34 (2.3%) of the 1465 cases that were tested for HPV subtypes. All other HPV subtypes had a prevalence of \<2% and included the following: types 31, 33, 35, 42, 45, 52, 56, 53, 55, 58, 59, 62, 72, and 73.

### HPV infection and PeCa infiltration {#sec3-7}

With respect to the correlation between HPV infection and invasive penile carcinoma, four studies[@ref15][@ref16][@ref22][@ref33] were included, and no significant difference was found (**[Supplementary Table 3](#T3){ref-type="table"}**). This finding may be due to the small sample size.

###### 

The invasiveness of penile carcinoma and the potential relationship with human papillomavirus infection

               *HPV infection*   *Total*   
  ------------ ----------------- --------- -----
  Group                                    
   *In situ*   106               131       237
   Invasive    124               142       266
  Total        230               273       503

*χ*^2^=0.181, df=1, *P*=0.671. HPV: human papillomavirus

### HPV infection in PeCa patients in various regions {#sec3-8}

The risks of HPV infection in patients with PeCa in disparate regions were analyzed by subgroup, and the results revealed that HPV infection rates varied on different continents. Six articles from Latin America were included and revealed that the random-effects model risk difference (RD) was 0.60 (95% CI: 0.43--0.76; *P* \< 0.00001 for heterogeneity) (**[Figure 3a](#F3){ref-type="fig"}**). The included studies consisted of 11 European articles, and the random-effects model RD was 0.50 (95% CI: 0.39--0.62; *P* \< 0.00001 for heterogeneity) (**[Figure 3b](#F3){ref-type="fig"}**). The articles from Asia demonstrated that the random-effects model RD was 0.35 (95% CI: 0.09--0.60; *P* \< 0.00001 for heterogeneity) (**[Figure 3c](#F3){ref-type="fig"}**). Significant heterogeneity was identified in the meta-analysis above. In addition, no sufficient studies from Africa or America were available for this meta-analysis. We also included three studies from Brazil, and the subgroup analysis revealed no significant change in HPV infection rates in Brazil from 2007 to 2017 (RD: 0.67, 95% CI: 0.61--0.72, χ^2^ = 1.68, *P* = 0.43) (**[Figure 4](#F4){ref-type="fig"}**), indicating a lack of heterogeneity and suggesting that the prevalence of HPV infection is stable and higher than the global average rate.

![Subgroup analysis of the risk difference between HPV and penile cancer in different continents. (**a**) Subgroup analysis of the risk difference between HPV and penile cancer in Latin America. (**b**) Subgroup analysis of the risk difference between HPV and penile cancer in Europe. (**c**) Subgroup analysis of the risk difference between HPV and penile cancer in Asia. HPV: human papillomavirus; CI: confidence interval; SE: standard error; IV: inverse variance methods; df: degree of freedom.](AJA-21-375-g003){#F3}

![Subgroup analysis of the risk difference between HPV and penile cancer in recent years in Brazil. HPV: human papillomavirus; CI: confidence interval; SE: standard error; IV: inverse variance methods; df: degree of freedom.](AJA-21-375-g004){#F4}

### Proportion of histologic types in penile carcinoma {#sec3-9}

Data from the selected studies were classified according to histological type. The overall HPV prevalence was obtained from a total of 1026 penile carcinoma cases: 597 keratinizing SCC cases (58.2%, 95% CI: 54.2%--62.2%), 28 nonkeratinizing SCC cases (2.7%, 95% CI: −3.3%--8.7%), 48 verrucous SCC cases (4.7%, 95% CI: −1.3%--10.7%), 40 warty SCC cases (3.9%, 95% CI: −2.1%--9.9%), 84 basaloid SCC cases (8.2%, 95% CI: 2.3%--14.1%), 47 cases of SCC with mixed warty and basaloid features (4.6%, 95% CI: −1.4%--10.6%), 25 papillary SCC cases (2.4%, 95% CI: −3.6%--8.4%), and 112 cases of other SCC mixed forms (10.9%, 95% CI: 5.1%--16.7%) (**[Supplementary Table 4](#T4){ref-type="table"}**). The histological subtypes of the other 481 cases were not known in the primary studies.

###### 

The constituent ratio of different histological types of penile cancer

  *Histological type*   *Constituent ratio (%)*   *Number of cases*   *95% CI*
  --------------------- ------------------------- ------------------- ------------
  Keratinizing SCC      58.2                      597                 54.2--62.2
  Basaloid SCC          8.2                       84                  2.3--14.1
  Verrucous SCC         4.7                       48                  −1.3--10.7
  Non-keratinizing      2.7                       28                  −3.3--8.7
  Warty                 3.9                       40                  −2.1--9.9
  Papillary             2.4                       25                  −3.6--8.4
  Warty-basaloid        4.6                       47                  −1.4--10.6
  Combined              4.4                       45                  −1.6--10.4
  Others                10.9                      112                 5.1--16.7
  Total                 100                       1026                −4.3--26.6

SCC: squamous cell carcinoma; CI: confidence interval

### Relationship between HPV type and histology of penile carcinoma {#sec3-10}

HPV infection in penile tumors is reportedly associated with various morphological changes, and determination of the subtype association can provide a better estimate of the HPV-related cancer burden and its preventable grade. The observed specific HPV contributions by histological type were as follows: basaloid SCC 85.5% (95% CI: 77.2%--93.8%); warty SCC 50.0% (95% CI: 35.2%--64.8%); nonkeratinizing/typical SCC 28.6% (95% CI: 11.9%--45.3%); keratinizing SCC 33.8% (95% CI: 29.9%--37.7%); and verrucous SCC 32.0% (95% CI: 16.7%--44.9%) (**[Supplementary Table 5](#T5){ref-type="table"}**).

###### 

The relationship between histological type and human papillomavirus infection

  *Histological type*   *HPV positive (%)*   *Total*   *95% CI %*
  --------------------- -------------------- --------- ------------
  Keratinizing SCC      33.8                 574       29.9--37.7
  Non-keratinizing      28.6                 28        11.9--45.3
  Basaloid SCC          85.5                 69        77.2--93.8
  Verrucous SCC         32.0                 50        16.7--44.9
  Warty                 50.0                 44        35.2--64.8
  Papillary             16.7                 24        1.8--31.6
  Combined types        28.3                 53        16.2--40.4

HPV: human papillomavirus; SCC: squamous cell carcinoma; CI: confidence interval

### Relationship between HPV infection and patient age {#sec3-11}

In our study, four studies[@ref22][@ref25][@ref26][@ref33] had available information on patient age at diagnosis, which allowed us to observe the relationship between HPV infection and patient age. A total of 274 samples with HPV types detected from four studies were divided into two groups: older than 60 years and younger than 60 years (**[Supplementary Table 6](#T6){ref-type="table"}**). Pearson\'s Chi-squared test was used to identify a correlation between these groups and the outcome (χ^2^ = 22.205, df = 1, *P* \< 0.001). However, the significance was restricted by the limited sample size, and patients may delay a visit to the doctor, thus causing a delay in diagnosis.

###### 

Age at penile cancer diagnosis and the relationship with human papillomavirus infection

               *HPV infection*   *Total*   
  ------------ ----------------- --------- -----
  Age (year)                               
   \<60        47                24        71
   \>60        102               101       203
  Total        149               125       274

*χ*^2^=22.205, df=1, *P*\<0.001. HPV: human papillomavirus

### HPV infection and the location of PeCa {#sec3-12}

Five articles[@ref15][@ref22][@ref26][@ref28][@ref33] containing 442 cases demonstrated the incidence rates of different sites of PeCa, with glans penis carcinoma being the most common, followed by foreskin carcinoma (**[Supplementary Table 7](#T7){ref-type="table"}**). Because studies examining the correlation between HPV infection and penile carcinoma locations are lacking, we could not define this relationship.

###### 

Distribution of tumor sites among penile cancers

  *Region*             *Number of cases*   *Component ratio (%)*
  -------------------- ------------------- -----------------------
  Glans                201                 45.50
  Foreskin             87                  19.70
  Corpus               5                   1.10
  Glans and foreskin   29                  6.60
  Non-evaluable        120                 27.10
  Total                442                 100

### HPV infection and differentiation of PeCa {#sec3-13}

Various degrees of differentiation exist in cases of PeCa. We collected 408 cases from 6 articles[@ref16][@ref17][@ref20][@ref24][@ref26][@ref33] containing the original tumor histological subtype and relevant statistics. Using Stata 15.0 for the Chi-squared test, we identified a significant statistical outcome (χ^2^ = 22.205, df = 2, *P* \< 0.001; **[Supplementary Table 8](#T8){ref-type="table"}**).

###### 

Constituent ratio of histological differentiation in penile tumors with human papillomavirus infection

  *Differentiation*   *HPV-positive*   *Total*   *HPV-positive rate (%)*
  ------------------- ---------------- --------- -------------------------
  Well                48               160       30.0
  Moderately          117              215       54.4
  Poorly              27               60        45.0

*χ*^2^=22.205, df=2, *P*\<0.001 HPV: human papillomavirus

DISCUSSION {#sec1-4}
==========

In the molecular evaluation, HPV infection was observed in 51% of lesions in the past 10 years, which is higher than the rate of 46.9% reported in earlier decades by Miralles-Guri *et al*.[@ref34] and the most common type found was HPV16. With respect to location, 45.50% of the tumors were located in the glans, and the most common types were squamous cell carcinoma (73.8%). These results correspond with those found in the literature.

Apart from types 6 and 11, almost no other single low-risk HPV has been found to contribute to PeCa. Previous studies have reported no significant difference in age among patients with various subtypes of SCC.[@ref21] The presence of HPV and the distribution of HPV genotypes were not associated with any single age group. However, our study found that, on average, diagnosis predominates in patients of advanced age (\>60 years), which may suggest that men seek health services very late in life and that young men are also affected but in smaller percentage.

Previous research has shown no correlation between HPV status and histological subtype (*P* = 0.51) or between HPV status and stage stratification.[@ref22] However, our findings indicated that the basaloid (85.5%, 95% CI: 77.2%--93.8%) and warty (50.0%, 95% CI: 35.2%--64.8%) subtypes are more likely to be HPV-positive than other subtypes. These findings are consistent with the WHO classification guidelines, indicating that HPV-related carcinomas are mostly basaloid and warty SCC.[@ref8] A higher proportion of basaloid cells correspond to a higher likelihood of HPV positivity in that tumor category. This cell type is morphologically similar to the predominant cell type observed in most invasive uterine cervical carcinomas, a known etiologically HPV-related cancer.[@ref21] HPV-positive tumors tend to exhibit warty and/or basaloid features and correspond to a moderate histological grade, whereas HPV-negative carcinomas usually correspond to well-differentiated tumors. Most reports validated the association of HPV with basaloid and warty carcinomas,[@ref35][@ref36] which is consistent with our results. Verrucous carcinoma is defined as a non-HPV-related subtype of SCC, with carcinoma cuniculatum as a variant in the WHO classification guidelines.[@ref8] However, the incidence of HPV-positive verrucous carcinoma was calculated to be 32% in our studies. Similarly, in some studies, approximately one-third of usual and verrucous carcinomas were also reported to be HPV positive.[@ref36] We consider that the differences in the prevalence of virus in penile carcinomas, either in general or special subtypes, are highly variable. In addition, non-HPV-related carcinomas may indicate no involvement of HPV in the pathogenesis, such as the P16^ink4a^ overexpression-negative carcinomas, but such cases may not include existing HPV infection, which has no role in the formation of cancer.

At present, the pathogenesis of PeCa is mostly related to overexpression of P16^ink4a^.[@ref18] In addition, Sebastian *et al*.[@ref37] detected two genes related to the pathogenesis of PeCa by immunohistochemistry: P16^ink4a^ overexpression identifies HPV-HR-induced penile carcinogenesis independent of the HPV-HR genotype, and positive p53 expression with P16^ink4a^ negativity identifies HPV-negative cancers. In summary, the present study indicates that HPV plays an important role in the pathogenesis of PeCa.

The presence of metastatic disease in the inguinal lymph nodes is one of the most important prognostic factors in PeCa.[@ref38] Unfortunately, the included data regarding the relationship between lymph node metastasis and HPV were fairly limited and of little statistical value; therefore, we did not involve lymph node-related results. However, a study by Feber *et al*.[@ref39] in which methylation of penile oncogenes was first sequenced showed that a 4-gene epi-signature accurately predicted lymph node metastasis in an independent cohort (area under the curve \[AUC\] of 89%). When used as a predictive methylation index for each sample, the predictive accuracy of this signature (90% methylation array and 89% for quantitative methylation specific polymerase chain reaction \[qMSP\]) to identify the presence of lymph node metastasis is at least comparable to if not better than the sensitivity of sentinel lymph node biopsy. They also explored epigenetic alterations associated with PeCa-related HPV infection and defined a 30-loci lineage without an HPV-specific epi-signature or HPV16 signature that is an independent predictor of disease-free survival and suggests distinct HPV subtype-specific epigenetic alterations.

This article identified genotype-specific HPV cases from studies using more sensitive PCR measures to allow investigation of HPV type distributions in PeCa in a large sample. These data also allowed us to investigate the differences between histological subtypes that are usually limited in the number of individual publications.

The included articles all included comparisons of cross-sectional studies, which may not be of high value. Studies on PeCa are limited, and most samples rely on FFPE tissue for HPV detection. Moreover, persuading healthy people to participate in HPV detection is extremely difficult, complicating the establishment of a control group. RCTs for related research have not been found.

Because the specific phenotype of mixed HPV infection was not clear in the included original literature, the analysis effect of the data may not be optimal. Fortunately, unknown mixed HPV infections accounted for only a small proportion of the overall sample. Due to the research type, the assessment of multiple infectious contributions is limited. Our results are based on cross-sectional data, which may not reflect the natural history of the disease. However, because the incidence of PeCa is relatively low, conducting a better longitudinal study to examine disease progression is difficult. HPV testing alone is not sufficient to prove cause and effect. However, HPV has been recognized as a tumor pathogen, and HPV infection may therefore have the same effect on penile tumors, given the similar histopathological features between men and women. Merck announced the completion of an initial study, demonstrating that Gardasil has 90% efficacy in preventing external genital lesions caused by HPV types 6, 11, 16, and 18 in men aged 16--26 years.[@ref40] More extensive and effective vaccinations should be applied to prevent HPV-related malignancies. As in cervical cancer, hrHPV is also a high-risk factor for PeCa; therefore, the countries and regions with high rates of PeCa and HPV infection, such as South Africa and Brazil, should promote HPV vaccination. HPV vaccines can even be considered for infertile men with HPV infection, spouses who are HPV positive, and gay people, especially with the development of therapeutic vaccines. This study may provide a reference for clinical diagnosis and treatment and suggests that the available HPV vaccine is urgently needed in high-risk populations.
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